Page last updated: 2024-12-07

2 alpha-methyl-9 alpha-fluorocortisol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2 alpha-methyl-9 alpha-fluorocortisol (2α-Me-9α-F-cortisol) is a synthetic steroid hormone that is a potent glucocorticoid receptor (GR) agonist.

Here's a breakdown of its features and why it's important in research:

**Features:**

* **Structure:** It's a modified version of cortisol, a natural hormone produced by the adrenal glands. The modifications, a methyl group at the 2 alpha position and a fluorine atom at the 9 alpha position, enhance its affinity for the GR.
* **High Potency:** 2α-Me-9α-F-cortisol is a very potent GR agonist, meaning it binds strongly to the GR and activates it. This results in strong glucocorticoid effects.
* **Long Half-life:** It has a longer half-life than natural cortisol, meaning it stays in the body for a longer time, providing sustained GR activation.

**Importance in Research:**

1. **Understanding Glucocorticoid Action:** Researchers use 2α-Me-9α-F-cortisol as a tool to investigate the role of the GR in various biological processes. Its high potency allows researchers to study the effects of GR activation in a controlled and efficient manner.
2. **Drug Development:** This compound serves as a template for developing new drugs with improved pharmacological properties. By understanding the structure-activity relationships of 2α-Me-9α-F-cortisol, researchers can design more effective and selective GR agonists for therapeutic applications.
3. **Studying Glucocorticoid-Related Diseases:** It plays a crucial role in studying diseases linked to glucocorticoid dysfunction, such as Cushing's syndrome and adrenal insufficiency. By understanding the actions of 2α-Me-9α-F-cortisol, researchers gain insights into disease mechanisms and potential therapeutic approaches.
4. **Investigating Anti-inflammatory Effects:** Glucocorticoids like 2α-Me-9α-F-cortisol are known for their potent anti-inflammatory properties. Researchers use this compound to explore the mechanisms of inflammation and identify new targets for anti-inflammatory drugs.

**Note:** 2α-Me-9α-F-cortisol is not currently used clinically due to its high potency and potential side effects. However, it is a valuable research tool that has contributed significantly to our understanding of glucocorticoid action and related diseases.

Cross-References

ID SourceID
PubMed CID101674
CHEMBL ID93948
SCHEMBL ID3685514
MeSH IDM0075512

Synonyms (16)

Synonym
11beta,17,21-trihydroxy-2alpha-methyl-9alphafluoro-4-pregnene-3,20-dione
CHEMBL93948 ,
432-34-8
(2r,8s,9r,10s,11s,13s,14s,17r)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-2,10,13-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(2alpha,11beta)-9-fluoro-11,17,21-trihydroxy-2-methylpregn-4-ene-3,20-dione
2alpha-methyl-9alpha-fluorocortisol
unii-l90otl9fg0
l90otl9fg0 ,
SCHEMBL3685514
pregn-4-ene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-2-methyl-, (2.alpha.,11.beta.)-
bdbm50474604
11b,17,21-trihydroxy-2a-methyl-9a-fluoro-4-pregnene-3,20-dione
2.alpha.-methyl-9.alpha.-fluorohydrocortisone
9.alpha.-fluoro-2.alpha.-methylcortisol
2-methyl-9.alpha.-fluorohydrocortisone, (2r)-
2.alpha.-methyl-9.alpha.-fluorocortisol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Corticosteroid-binding globulinHomo sapiens (human)Ki1.58490.01323.248110.0000AID51055
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
glucocorticoid metabolic processCorticosteroid-binding globulinHomo sapiens (human)
negative regulation of endopeptidase activityCorticosteroid-binding globulinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
steroid bindingCorticosteroid-binding globulinHomo sapiens (human)
serine-type endopeptidase inhibitor activityCorticosteroid-binding globulinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
extracellular regionCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
extracellular exosomeCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID51053Compound was evaluated for its binding affinity towards the human corticosteroid binding globulin1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Self-organizing molecular field analysis: a tool for structure-activity studies.
AID51054Binding affinity for corticosteroid binding globulin is expressed as log(1/k)1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID51056Binding affinity to the corticosteroid-binding globulin (CBG) receptor.2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors.
AID51062In silico steroid binding affinity to transport protein corticosteroid binding globulin1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID51048In silico binding affinity to human corticosteriod binding globulin1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID51058Binding affinity towards corticosteroid-binding globulin (CBG)2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
AID51059Binding affinity to corticosteroid binding globulin1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices.
AID51052In silico binding affinity to corticosteroid binding globulin (CBG)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations.
AID51055Binding affinity to human CBG receptor (corticosteroid-binding globulins)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Comparative molecular active site analysis (CoMASA). 1. An approach to rapid evaluation of 3D QSAR.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (66.67)18.2507
2000's3 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.90 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]